Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients.
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.
Located in the heart of Cambridge with a new laboratory facility in Bedford, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work. We offer competitive salary and benefits, and potential for employee ownership through stock options.
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $325.04M
Founded date: 2015
Investors 7
Date | Name | Website |
- | ShangPharm... | spiivc.com |
- | Takeda Ven... | takeda.com |
15.09.2021 | RA Capital... | racap.com |
- | TCG Crosso... | tcgcrossov... |
- | Atlas Vent... | atlasventu... |
- | NFLS - Piv... | pivotalbio... |
- | GV | gv.com |
Funding Rounds 3
Date | Series | Amount | Investors |
03.04.2024 | Series C | $160.5M | - |
09.09.2021 | Series B | $115.04M | - |
06.12.2017 | Series A | $49.5M | - |
Mentions in press and media 20
Date | Title | Description | Source |
20.04.2024 | The Melanoma Research Foundation to host the New England Mil... | New England Miles for Melanoma The Melanoma Research Foundation (MRF) is thrilled to announce one of... | prweb.com/... |
08.04.2024 | Obsidian Therapeutics Secures $160.5M in Series C Funding | Obsidian Therapeutics, a cutting-edge biotech company based in Cambridge, MA, has successfully raise... | parsers.vc... |
03.04.2024 | Obsidian Therapeutics Raises $160.5M in Series C Funding | Obsidian Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company, raised $160.5M in... | finsmes.co... |
21.02.2024 | A watershed moment for cancer therapies has arrived | A new class of cancer treatments that harness the body's immune system to fight tumors is being hail... | axios.com/... |
10.12.2021 | Flagship on center stage: Axcella’s new CMO likens the b... | Margaret Koziel Margaret Koziel has bounced back and forth between academia and biotech through... | endpts.com... |
10.09.2021 | The question that defines venture capital firm Benchmark | For Benchmark, I imagine they take the question with a hint of exasperation, like late stage compani... | fortune.co... |
10.09.2021 | The question that defines venture capital firm Benchmark | For Benchmark, I imagine they take the question with a hint of exasperation, like late stage compani... | fortune.co... |
09.09.2021 | Obsidian Therapeutics Announces Closing of $115 Million Seri... | prnewswire... | |
09.09.2021 | Obsidian Therapeutics Announces Closing of $115 Million Seri... | - | tcgcrossov... |
09.09.2021 | Obsidian Therapeutics Closes $115M Series B Financing | Obsidian Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company pioneering engineered ce... | finsmes.co... |
Show more